Biocept

Biocept Book Value Growth

The Book Value Growth of Biocept (BIOCQ) as of Nov 20, 2026 is -76.36 %. In the previous year, Book Value Growth was 58.19 % — a change of -231.22% (lower).

Book Value Growth

-76.36 %

YoY

-231.22%

Last updated:

Book Value Growth of Biocept is 2022 -76.36 % . Book Value Growth of Biocept was 2021 58.19 % . It decreases by -231.22% lower compared to the previous year.

The Biocept Book Value Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value Growth
Date
Book Value Growth
Jan 1, 2015
1,777.27 USD
Jan 1, 2016
-82.11 USD
Jan 1, 2017
96.97 USD
Jan 1, 2018
133.85 USD
Jan 1, 2019
268.44 USD
Jan 1, 2020
111.53 USD
Jan 1, 2021
58.19 USD
Jan 1, 2022
-76.36 USD
The Biocept Book Value Growth history
YEARBook Value GrowthYoY
-76.36 %-231.22%
58.19 %-47.82%
111.53 %-58.45%
268.44 %+100.56%
133.85 %+38.03%
96.97 %-218.09%
-82.11 %-104.62%
1,777.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept, Inc. generates revenue through its oncology laboratory services, focusing on the detection of rare cells such as circulating tumor cells. The company markets its CNSide brand, which includes a suite of cellular and molecular technologies for central nervous system disease management. Its diagnostic assays, such as cell capture and enumeration, immunocytochemistry, FISH, and NGS, are commercialized for detecting various carcinomas and melanoma in blood and cerebrospinal fluid. Medical professionals and healthcare providers purchase these services to aid in patient diagnosis and treatment management. The CNSide product suite is designed for use in cerebrospinal fluid analysis, targeting solid tumor patients. Biocept's assays are specifically tailored for identifying rare tumor cells and cell-free tumor DNA, supporting clinical decision-making. The company's focus on solid tumors and CNS disease management positions it within the diagnostic laboratory services market, where healthcare institutions seek advanced tools for oncology care. Biocept's commercialized assays include cell capture, enumeration, immunocytochemistry, FISH, and NGS, all under the CNSide brand. These products are sold to medical professionals who require precise diagnostic tools for central nervous system disease management. The company's offerings are targeted at healthcare providers managing patients with solid tumors, particularly those requiring CSF analysis for disease monitoring and treatment planning. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Book Value Growth of Biocept is -76.36 % in 2022.

On Eulerpool you can find the complete historical development of Book Value Growth Biocept since 2006 – with annual values, charts, and detailed analysis.

Book value growth measures the percentage increase in shareholders' equity. It indicates how effectively the company retains and grows its net assets.

To evaluate Book Value Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Book Value Growth.

Book Value Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Book Value Growth's Biocept historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Biocept

All Key Metrics — Biocept